跳到正文
BioPharm International·· 4 天前AI 评分36

mAbxience 投资并承接 OncoPrecision ADC 候选药 ONC001 抗体开发与生产

mAbxience Backs OncoPrecision ADC With Investment, Manufacturing Deal

AI 导读

mAbxience 与 OncoPrecision 于 2026 年 11 月 18 日宣布就后者先导 ADC 候选药 ONC001 达成投资、开发与生产协议,mAbxience 将负责从细胞株开发到工艺与分析开发的抗体部分,并生产 GMP 级物料以支持计划的 1 期试验。

正文 · 原文

mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.

mAbxience and OncoPrecision announced on November 18, 2026, an investment, development, and manufacturing agreement for ONC001, OncoPrecision's lead antibody-drug conjugate (ADC) candidate.¹ Under the agreement, mAbxience will handle the development program for the antibody portion of ONC001, from cell line development through process and analytical development, and will manufacture good manufacturing practice (GMP)-grade material to support a planned phase 1 trial.¹

Key facts

  • Candidate: ONC001 (OncoPrecision)
  • Class: First-in-class CD64-targeting antibody-drug conjugate
  • Mechanism: Eliminates leukemic monocytes and tumor-associated macrophages
  • Lead indications: Monocytic AML and chronic myelomonocytic leukemia
  • Partner: mAbxience, a wholly owned company of Fresenius SE & Co. KGaA
  • Scope: Cell line development through process and analytical development; GMP supply
  • Investment: Strategic equity stake in OncoPrecision; terms confidential
  • Governance: mAbxience CEO Jurgen Van Broeck joins OncoPrecision's board as an observer
  • Stage: Preclinical, advancing toward a planned phase 1 trial
  • First disclosure: Oral presentation at the 2025 ASH Annual Meeting

“By bringing together our capabilities and long-term commitment, we aim to accelerate ONC001's path to the clinic while creating sustainable value for both companies,” said José Ramón Millán, global portfolio, contract development and manufacturing organization (CDMO) and partnering director at mAbxience, in a company press release.¹

What is ONC001?

ONC001 is a CD64-targeting ADC designed to eliminate leukemic monocytes and tumor-associated macrophages, with lead indications in monocytic acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), both aggressive blood cancers with few effective options and a median survival measured in months, according to the companies.¹ The candidate was first publicly disclosed in an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting and is moving toward first-in-human studies.¹

OncoPrecision, headquartered in New York City, develops precision therapies for hard-to-treat cancers by combining patient-derived biology with artificial intelligence.¹ mAbxience is a wholly owned company of Fresenius SE & Co. KGaA.¹

What are the terms?

mAbxience will contribute scientific expertise, industrial capabilities, and its Smart CoGs approach, supporting the program through manufacture of the first GMP batch for clinical use.¹ The company has also made a strategic investment in OncoPrecision, and Jurgen Van Broeck, chief executive officer of mAbxience, will join OncoPrecision's board of directors as an observer.¹ Financial terms of the investment were not disclosed.¹

“We're thrilled to partner with mAbxience to accelerate ONC001's path to the clinic through their world-class manufacturing capabilities and regulatory expertise,” said Tarek Ali Zaki, cofounder and CEO, OncoPrecision, in the release.¹

How does this deal fit broader ADC manufacturing activity?

The agreement lands amid sustained investment in ADC manufacturing capacity. Lonza said in October 2026 that it would convert existing mid-scale bioconjugation suites at its Visp, Switzerland, site to a standardized single-use platform with 500-L capacity, scheduled for completion in 2027, and add a large-scale facility with 3 multiproduct suites at scales of up to 3000 L, operational from 2028.² That announcement followed a June 2026 expansion of payload-linker capacity at the same site.³

Days later, Lonza agreed to acquire Merck KGaA's US CDMO business, 5 sites and about 1100 employees, at a total enterprise valuation in the low- to mid-triple-digit millions of Swiss francs.⁴ The deal adds bioconjugates work in St. Louis, Missouri, and high-potency payload-linker production in Madison and Verona, Wisconsin.⁴ “With high demand for bioconjugates and viral vectors,” said Lonza CEO Wolfgang Wienand, PhD, in a press release at the time of the announcement, the sites will strengthen the company's ability to support customers from innovation through commercial supply.⁴

Licensing activity has also run in parallel. In November 2026, Boehringer Ingelheim signed a partnership with Sino Biopharmaceutical covering 6 preclinical biologic programs, paying $358 million in upfront and near-term payments, with up to $7 billion in milestones.⁵

What are the limitations?

Financial terms of the mAbxience investment and the development agreement were not disclosed, and the release did not disclose a timeline for the phase 1 trial, a target start date, or a manufacturing site. ONC001 remains preclinical. Data disclosed at the 2025 ASH meeting were presented in a conference abstract rather than a peer-reviewed journal, and the release does not summarize those results. mAbxience's role covers the antibody moiety, but the companies did not disclose who will handle payload-linker synthesis or conjugation.

References

  1. mAbxience. mAbxience and OncoPrecision announce manufacturing and investment agreement for OncoPrecision's ADC candidate ONC001. Press release. Published November 18, 2026. Accessed November 18, 2026. https://www.prnewswire.com/news-releases/mabxience-and-oncoprecision-announce-manufacturing-and-investment-agreement-for-oncoprecisions-adc-candidate-onc001-302943684.html
  2. Lonza. Lonza further expands bioconjugation manufacturing to support growing ADC demand. Press release. Published October 29, 2026. Accessed November 18, 2026. https://www.lonza.com/media-advisories/2026-10-29-14-00
  3. Lonza. Lonza expands HPAPI capacity in Visp, further supporting its position in payload-linker manufacturing. Press release. Published June 30, 2026. Accessed November 18, 2026. https://www.lonza.com/news/2026-06-30-07-00
  4. Lonza. Lonza signs agreement to acquire US CDMO network from Merck KGaA, Darmstadt, Germany, and significantly expands its US presence. Press release. Published November 3, 2026. Accessed November 18, 2026. https://www.lonza.com/news/2026-11-03-07-00
  5. Boehringer Ingelheim. Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies. News release. Published November 4, 2026. Accessed November 18, 2026. https://www.boehringer-ingelheim.com/human-health/boehringer-announces-new-oncology-partnership-sbp-group

Related to this article

Advancing Healthcare with CAR T-Cell Therapy: A New Frontier in Medicine | Image credit: © Funny - © Funny - stock.adobe.com

November 18th, 2026

Verismo will pair Stanford's PACK-IT lentiviral technology with its KIR-CAR platform to pursue off-the-shelf, in vivo CAR T therapies for cancer.

Read more

Small-Molecule Agility Can Inform Biologics Manufacturing, Says Merck

November 17th, 2026

Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.

Read more

Older woman with short gray hair, wearing a blue T-shirt, sitting on a beige couch with both hands gripping her shoulders and neck, eyes closed in discomfort. | Image Credit: © Graphicroyalty - stock.adobe.com

November 17th, 2026

FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.

Read more

Fundus photograph of a human retina showing the pale optic disc on the left, branching red blood vessels and a darker spot at the center of the macula. | Image Credit: © Panama - stock.adobe.com

November 18th, 2026

Visara has dosed the first patient in ASCEND, a roughly 244-patient, head-to-head phase 2b trial comparing two doses of its tetravalent VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in treatment-naïve wet AMD. The study will test dosing intervals of up to seven months and select the dose for a global phase 3 program planned as early as 2027.

Read more

Film X-ray shoulder radiograph show Enchondroma disease at arm bone. Enchondrama is a benign tumor of cartilage grow within bone and expand it. Highlight on mass lesion. Medical oncology concept | Image credit: © Joel bubble ben - © Joel bubble ben - stock.adobe.com

November 17th, 2026

Marrow's lead candidate MAR-101 aims to reactivate fetal hemoglobin in sickle cell disease and beta thalassemia through in vivo bone marrow targeting.

Read more

Bottles of Vaccine and syringe - 3D illustration  | Image credit: © peterschreiber.media - © peterschreiber.media - stock.adobe.com

November 17th, 2026

Galinpepimut-S maintenance extended median overall survival to 24.0 vs 14.7 months in transplant-ineligible AML patients in second or later remission.

Read more

A professional male physician, wearing a white lab coat, is presenting a detailed anatomical model of the kidneys, urinary tract, and male reproductive organs to a patient, while explaining kidney fun | Image credit: © Yanisa - © Yanisa - stock.adobe.com

November 16th, 2026

Obinutuzumab produced complete proteinuria remission in 36.1% of primary membranous nephropathy patients at 2 years vs 5.7% with tacrolimus.

Read more

Muscles of arm for physiology education. | Image credit: © tonaquatic - © tonaquatic - stock.adobe.com

November 16th, 2026

Once-weekly self-injected gefurulimab improved daily-living scores in AChR-positive generalized myasthenia gravis in the 260-patient PREVAIL trial.

Read more

来源:BioPharm International · biopharminternational.com